Fresh off fundraising trail, Georgian Partners leads TraceLink’s $93 mln round

Georgian Partners, which only weeks ago closed its fourth fund, is backing a software provider that aims to rid the global marketplace of counterfeit drugs. TraceLink, a Boston pharmaceuticals-tracking platform, said today that it raised a US$93 million financing led by the Canadian growth equity firm. Georgian Partner Tyson Baber joined the board. Founded in 2009, TraceLink provides a network for drugmakers and other stakeholders in the global life-sciences supply chain to connect and share information in real time. Along with leading its round, Georgian will support the company's artificial intelligence and machine learning strategy.

FeaturedCanadaNorth AmericaFeaturedBriefs